COMMUNIQUÉ DE PRESSE

par FERMENTALG (EPA:FALG)

A 1st half-year 2024 marked by the success of the commercial relaunch and the strengthening of strategic alliances

Libourne - September 17, 2024 - Fermentalg (Euronext Growth / ALGAE), expert French microalgae company, presents its results for the 1st half-year of the 2024 financial year, following approval of the accounts by the Board of Directors at its meeting today[1]. These results confirm the relevance of the new strategic plan and its two pillars: boosting sales by opening up new markets and strengthening strategic partnerships.

2.7-fold increase in sales of DHA Origins® and outlook confirmed

Under the impetus of the new Chief Executive Officer, and in line with the roadmap presented in December 2023, Fermentalg recorded very strong sales momentum in the 1er half-year 2024.

By the end of June, the Company had generated sales of €6.3m, a 2.7-fold increase on the 1er half-year 2023. This is the best commercial half-year recorded by the Company since the launch of the DHA Origins® range, the omega-3-rich algal oil, in 2018.

This performance is the fruit of a strengthened marketing and sales team and a rethought strategy based on opening up new markets. Over the 1er half-year, Fermentalg booked its first orders in the promising premium dietary supplements and petfood segments. This offensive strategy will continue over the coming months, with an expansion into human and animal nutrition market segments.

Thanks to these new outlets, Fermentalg confirms its annual sales target of at least €12 million, 3 times higher than 2023 (€4 million), even though the market context has hardened in recent months, with fish oil prices falling but remaining above historical levels.

Strategic partnership with Huvepharma group gains momentum

At the end of 2023, Fermentalg formed a strategic alliance with the Huvepharma group, the European leader in large scale precision fermentation for the animal and human health sectors. This alliance was ramped up during the 1er half-year 2024, with in particular:

  • The successful industrial transfer of DHA Origins® production to Huvepharma's Bulgarian plants: the first volume production runs have started successfully, yields are gradually improving and the target conditions for industrial performance are now being met, enabling ultimate gains in profitability and competitiveness.
  • The launch of EverzureTM, the only acid-stable natural blue colorant developed by Fermentalg (see below).
  • Huvepharma's participation in Fermentalg's successful capital increase in June 2024, making it the Company's largest shareholder with just over 20% of the capital and voting rights. In this context, the General Meeting of Shareholders held today appointed Anguel Jeliazkov Ivanov, Vice-President at Huvepharma group to the Company's Board of Directors.

Continued developments with Givaudan around EverzureTM

In line with its strategy of forging alliances with partners who can leverage its industrial and commercial performance, Fermentalg pursued its partnership with Givaudan, a world leader in food colorants, over the 1er half-year around EverzureTM , with the following advances:

  • In terms of technological and industrial development, the work carried out by Fermentalg at pilot scale has been finalized, and the transfer of production to industrial scale at Huvepharma, currently underway, is due to be completed in the second half of the year.
  • On the commercial front, Givaudan has carried out sampling tests with potential partners, confirming initial interest. Discussions are now continuing with a view to placing the first orders.
  • On the regulatory front, approval files are still being examined with a view to first approvals in Europe and the United States, where FDA approval should be expected between late 2024 and early 2025, given the comparable age of the dossiers.

Slight improvement in operating income as sales and manufacturing ramp up

(in K€)S1 2023S1 2024
Net Sales2 3406 319
Operating income before share-based payments and non-current items-4 742-4 360
Operating income after share-based payments and non-current items-4 594-4 351
Cost of net financial debt-103-122
Other financial income and expense-686-774
Share in net income (loss) of associates-289-415
Net income (loss)-5 673-5 662

Against this backdrop of ramping up sales and optimizing production facilities, Fermentalg reported stable half-year net result overall compare to 2023.

In detail, operating income, before share-based payments and non-current items, came to -€4.4m, compared with -€4.7m in the 1er half 2023. The 2.7-fold increase in sales had a beneficial effect, partially offset by:

  • A margin on direct costs temporarily impacted by costs linked to the transfer and optimization of the industrial process, the pricing policy applied in the phase of commercial conquest in new segments, and the destocking of production carried out in 2023 at high cost by the former subcontractor (see below).
  • A +10% increase in operating expenses, reflecting the strengthening of sales teams and marketing actions.
  • Research and development costs up 5%, due to lower capitalization of these costs (€0.4m vs. €1.3m), with total R&D expenditure down €0.9m.

Net income was stable at -5.6 M€, after taking into account the non-cash accounting charge for calculating the fair value of convertible bonds issued in 2023 (-0.8 M€) and the share of profit of the subsidiary CarbonWorks (-0.4 M€ versus -0.3 M€ in the 1er half-year 2023).

Cash position up by €10 million

(in K€)31/12/202330/06/2024
Shareholders' equity30 84639 050
Non-current borrowings13 9738 673
Current borrowings1 3815 323
Cash and cash equivalents11 16221 265

At June 30, 2024, Fermentalg had gross cash of €21.3 million, up €10.1 million in 6 months, and shareholders' equity of €39.1 million.

This significant increase in cash flow was made possible by the success of the capital increase for a net amount of €11.8 million carried out in June 2024, which saw Huvepharma acquire a stake and Bpifrance confirm its financial support for the Company, and by inventory reduction efforts (€4.9 million) at the start of the year. These flows offset the company's current expenses (cash flow of €3.3 million) and R&D investments (€0.4 million).

Gross financial debt, amounting to €14.0 million at the end of June 2024, fell by €1.5 million during the half-year. It is mainly made up of repayable advances (5.8 M€), the convertible bond held by the Givaudan group (3.7 M€) and the balance of the bonds issued in March 2023 (3.2 M€), over 60% of which have already been converted.

At present, the Company considers that its liquidity horizon extends beyond the next 12 months.

Next publication: sales for the 3ème quarter 2024,
October 3, 2024 (after market close)

About Fermentalg

An expert in the research and bioindustrial exploitation of microalgae, Fermentalg aims to offer sustainable solutions and innovative products that contribute to the development of healthy, natural and high-performance products . Our business: the development, production and marketing of sustainable solutions and active ingredients derived from microalgae, for nutrition, health and the environment. Nutritional lipids, alternative proteins, natural food colorings and innovative environmental solutions make up our company's current and future offering. Fermentalg shares are listed on Euronext Growth Paris (FR0011271600 - ALGAE) and are PEA-PME eligible. It has received an Exemplary rating (90/100) from EthiFinance ESG Ratings, a rating agency specializing in the ESG performance of SMEs listed on European markets, in favor of Socially Responsible Investment (SRI).

For further information: www.fermentalg.com

     

 

Contact for journalists:Investor Relations :
ACTUS finance and communication
Fatou-Kiné N'DIAYE
Telephone: +33 (0)1 53 67 36 34
fndiaye@actus.fr
ACTUS finance and communication
Jérôme FABREGUETTES LEIB
Telephone: +33 (0)1 53 67 36 78
fermentalg@actus.fr

 

Appendices

STATEMENT OF COMPREHENSIVE INCOME
(in thousands of euros)
 30/06/202431/12/202330/06/2023
Sales figures 6 3194 0582 340
Other business-related products 8131 063538
Cost of sales -5 247-3 522-1 860
Research and development costs -2 099-4 414-1 998
Operating expenses excluding R&D -4 145-8 091-3 762
Other current operating income and expenses 000
Operating income before share-based payments and non-current items -4 360-10 907-4 742
Personnel expenses related to share-based payments -40-167-76
Other non-recurring operating income and expenses 49-734225
Operating income after share-based payments and non-current items -4 351-11 808-4 594
Income from cash and cash equivalents 86294113
Gross cost of debt -208-482-216
Cost of net financial debt -122-188-103
Other financial income and expense -774-1 277-686
Net tax expense 000
Share in net income of associates -415-875-289
Net income -5 662-14 148-5 673
Minority interests 000
NET INCOME, GROUP SHARE -5 662-14 148-5 673
Other comprehensive income (actuarial gains and losses on pension obligations, not recyclable in the income statement) 0520
OVERALL NET INCOME -5 662-14 096-5 673
Minority interests 000
NET INCOME ATTRIBUTABLE TO EQUITY HOLDERS OF THE PARENT -5 662-14 096-5 673
Earnings per share (in €) -0,10-0,32-0,13
Diluted earnings per share (in €) -0,10-0,32-0,13

 

BALANCE SHEET
(in thousands of euros)
 30/06/202431/12/202330/06/2023
ASSETS    
Intangible assets 14 99514 98914 660
Property, plant and equipment 10 19510 81511 998
Investments in associates 2 7023 1173 702
Financial and other non-current assets 4854283
Deferred tax assets 000
TOTAL NON-CURRENT ASSETS 27 94028 97530 644
Stocks 1 9346 8068 358
Trade receivables and other assets related to customer contracts 2 0401 0781 292
Other receivables 3 2452 2233 127
Corporate income tax receivables 000
Cash and cash equivalents 21 26511 16215 399
TOTAL CURRENT ASSETS 28 48421 26928 176
TOTAL ASSETS 56 42550 24458 820
LIABILITIES    
Capital 3 5152 0521 714
Bonus 38 36037 81036 203
Reserves and RAN 2 8385 0804 673
Total net income -5 662-14 096-5 672
Equity attributable to equity holders of the parent 39 05030 84636 918
Minority interests 000
TOTAL SHAREHOLDERS' EQUITY 39 05030 84636 918
Non-current borrowings 8 67313 97315 858
Retirement commitments 321282298
Other non-current liabilities 623681479
TOTAL NON-CURRENT LIABILITIES 000
Current borrowings 5 3231 3811 430
Provisions for current risks 017610
Trade payables 8911 4362 204
Corporate income tax liabilities 000
Other current liabilities 1 5441 4691 623
TOTAL CURRENT LIABILITIES 7 7584 4625 267
TOTAL LIABILITIES 56 42550 24458 820

 

 

CASH FLOW
(in thousands of euros)
 30/06/202431/12/202330/06/2023
Total net income -5 662-14 148-5 673
Depreciation, amortization and provisions (excluding current assets) 1 1833 1551 139
Share-based payment expense 4016788
Share of profit of associates 415875289
Capital gains/losses on disposals -4820
Share of subsidies in income -58-237-58
Change in fair value of OCAs 6401 049388
Cash flow -3 490-9 138-3 826
Gross cost of debt 208482216
Income tax expense 000
Cash flow before cost of debt
and tax
 -3 282-8 655-3 610
Change in inventories 4 872-395-1 947
Change in trade receivables (trade receivables, other assets and liabilities related to customer contracts) -96226652
Change in trade payables and related accounts -585-93678
Change in other current assets and liabilities (a) -1 033215-850
Change in operating working capital requirement 2 292-7-2 067
NET CASH PROVIDED BY OPERATING ACTIVITIES -990-8 662-5 677
Production of fixed assets (capitalized R&D) -427-1 952-1 302
Share of grants and CIR related to capitalized development projects 132461615
Acquisitions of other tangible and intangible assets -383-472-298
Investments in or acquisition of associates (MEQ) 000
Change in payables on fixed assets 109-63-65
Change in other non-current assets and liabilities 624717
Disposals of property, plant and equipment and intangible assets 18150
Disposal of financial assets 000
NET CASH FLOWS FROM INVESTING ACTIVITIES -545-1 765-1 032
Capital increase linked to the parent company 11 80273-12
Acquisitions and disposals of treasury shares -6-22-3
New borrowings and other financial liabilities 1686 4126 412
Repayment of borrowings and other financial liabilities -315-750-175
Change in current accounts 000
Interest paid on borrowings -10-26-14
NET CASH FLOWS FROM FINANCING ACTIVITIES 11 6385 6866 208
Change in cash and cash equivalents 10 103-4 741-502
Opening cash position 11 16215 90215 902
Closing cash position 21 26511 16215 400
(a): of which change in Research Tax Credit (CIR): -6843650

 


[1] The auditors' limited review procedures on these financial statements have been performed. The interim financial report will be published no later than September 30, 2024.



Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
Voir toutes les actualités de FERMENTALG